Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
4.61
USD
|
+1.77%
|
|
-2.64%
|
+11.89%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11.09
|
48.54
|
73.55
|
43.85
|
87.2
|
157.9
|
-
|
-
|
Enterprise Value (EV)
1 |
11.09
|
48.54
|
73.55
|
43.85
|
87.2
|
157.9
|
157.9
|
157.9
|
P/E ratio
|
-0.27
x
|
-1.49
x
|
-1.91
x
|
-0.61
x
|
-2.75
x
|
-4.51
x
|
-4.48
x
|
-12.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
439
x
|
4.19
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
439
x
|
4.19
x
|
EV / EBITDA
|
-742,366
x
|
-
|
-2,239,330
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.73
x
|
-
|
-2.5
x
|
-
|
-
|
-4.75
x
|
-3.39
x
|
-6.12
x
|
FCF Yield
|
-138%
|
-
|
-40%
|
-
|
-
|
-21%
|
-29.5%
|
-16.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,047
|
5,993
|
9,454
|
17,897
|
21,166
|
34,252
|
-
|
-
|
Reference price
2 |
10.60
|
8.100
|
7.780
|
2.450
|
4.120
|
4.610
|
4.610
|
4.610
|
Announcement Date
|
3/13/20
|
3/11/21
|
3/10/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.36
|
37.72
|
EBITDA
|
-14.94
|
-
|
-32.84
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.53
|
-14.75
|
-33.09
|
-40.8
|
-27.25
|
-30.83
|
-37.74
|
-8.807
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-10,484.17%
|
-23.35%
|
Earnings before Tax (EBT)
1 |
-16.4
|
-14.73
|
-33.15
|
-42.35
|
-29.82
|
-32
|
-42.15
|
-9.422
|
Net income
1 |
-16.4
|
-14.73
|
-33.15
|
-42.35
|
-29.82
|
-31.83
|
-38.56
|
-9.422
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-10,710.28%
|
-24.98%
|
EPS
2 |
-39.80
|
-5.420
|
-4.080
|
-4.000
|
-1.500
|
-1.021
|
-1.028
|
-0.3800
|
Free Cash Flow
1 |
-15.27
|
-
|
-29.44
|
-
|
-
|
-33.21
|
-46.56
|
-25.79
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-12,932.78%
|
-68.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/11/21
|
3/10/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.115
|
-7.226
|
-10.07
|
-12.64
|
-10.86
|
-8.578
|
-7.714
|
-6.572
|
-4.386
|
5.982
|
-7.011
|
-8.358
|
-10.21
|
-11.02
|
-15.14
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.151
|
-7.573
|
-10.47
|
-13.08
|
-11.23
|
-8.992
|
-8.239
|
-7.108
|
-5.476
|
-6.494
|
-7.065
|
-7.956
|
-10.6
|
-11.26
|
-15.38
|
Net income
1 |
-7.151
|
-7.573
|
-10.47
|
-13.08
|
-11.23
|
-8.992
|
-8.239
|
-7.108
|
-5.476
|
-6.494
|
-7.332
|
-8.678
|
-10.53
|
-11.26
|
-15.38
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7600
|
-0.8000
|
-1.080
|
-1.350
|
-0.8300
|
-0.5000
|
-0.4300
|
-0.3400
|
-0.2600
|
-0.2600
|
-0.2280
|
-0.2600
|
-0.2820
|
-0.2800
|
-0.3850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/12/22
|
8/11/22
|
11/14/22
|
3/16/23
|
5/9/23
|
8/14/23
|
11/9/23
|
3/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-15.3
|
-
|
-29.4
|
-
|
-
|
-33.2
|
-46.6
|
-25.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
-
|
-
|
-
|
0.26
|
0.31
|
0.38
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
87.22%
|
1.01%
|
Announcement Date
|
3/13/20
|
3/11/21
|
3/10/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
4.61
USD Average target price
19.75
USD Spread / Average Target +328.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.89% | 158M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|